Dr. Sattar is a surgical pathologist with a subspecialty focus in breast pathology.
University of Chicago Medicine
Residency - Anatomic and Clinical Pathology
2015
The University of Chicago Pritzker School of Medicine
MD
2001
The University of Chicago
BA - Biology
1993
Low-affinity CD8+ T cells provide interclonal help to high-affinity CD8+ T cells to augment alloimmunity.
Low-affinity CD8+ T cells provide interclonal help to high-affinity CD8+ T cells to augment alloimmunity. Am J Transplant. 2024 Jan 14.
PMID: 38228228
Heterogeneity in allospecific T cell function in transplant-tolerant hosts determines susceptibility to rejection following infection.
Heterogeneity in allospecific T cell function in transplant-tolerant hosts determines susceptibility to rejection following infection. J Clin Invest. 2023 11 01; 133(21).
PMID: 37676735
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.
PMID: 36069821
Host-versus-commensal immune responses participate in the rejection of colonized solid organ transplants.
Host-versus-commensal immune responses participate in the rejection of colonized solid organ transplants. J Clin Invest. 2022 09 01; 132(17).
PMID: 35834335
Oral alloantigen exposure promotes donor-specific tolerance in a mouse model of minor-mismatched skin transplantation.
Oral alloantigen exposure promotes donor-specific tolerance in a mouse model of minor-mismatched skin transplantation. Am J Transplant. 2022 10; 22(10):2348-2359.
PMID: 35633180
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823.
PMID: 35513244
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
PMID: 34529000
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
PMID: 32701140
Angular restriction fluorescence optical projection tomography to localize micrometastases in lymph nodes.
Angular restriction fluorescence optical projection tomography to localize micrometastases in lymph nodes. J Biomed Opt. 2019 11; 24(11):1-4.
PMID: 31705637
Paired-Agent Fluorescence Molecular Imaging of Sentinel Lymph Nodes Using Indocyanine Green as a Control Agent for Antibody-Based Targeted Agents.
Paired-Agent Fluorescence Molecular Imaging of Sentinel Lymph Nodes Using Indocyanine Green as a Control Agent for Antibody-Based Targeted Agents. Contrast Media Mol Imaging. 2019; 2019:7561862.
PMID: 30718985